Iambic Therapeutics IPO Targets $806M Valuation
Nvidia-backed Iambic Therapeutics plans a Nasdaq IPO at $15 to $17 a share, valuing the AI drug discovery firm at up to about $806 million.
Nvidia-backed Iambic Therapeutics plans a Nasdaq IPO at $15 to $17 a share, valuing the AI drug discovery firm at up to about $806 million.